Healthcare, Pharma & Life Sciences

KELLS AI Dental Scan Wins Singapore's First HSA Nod for Consumer Use

Image
KELLS AI Dental Scan Wins Singapore's First HSA Nod for Consumer Use

Singapore – September 19, 2026 -- KELLS' AI Dental Scan has become the first AI-powered dental screening tool registered as a Class B medical device by Singapore's Health Sciences Authority (HSA) for direct consumer use, the company announced.

HSA registration validates KELLS' proprietary AI for at-home dental screening

The clearance allows users to capture smartphone images of their teeth, which KELLS' AI then analyzes to flag potential oral health concerns and indicate when professional dental care may be warranted. The registration marks a regulatory first for consumer-facing dental AI tools in Singapore and supports the company's expansion in the market.

Stryker Adds Prophecy Planning to Incompass Ankle System

Image
Stryker Adds Prophecy Planning to Incompass Ankle System

Portage, Mich. – September 19, 2026 -- Stryker will launch Prophecy Surgical Planning for its Incompass Total Ankle System and unveil Hoffmann LRF smartHEX at the 2026 American Orthopaedic Foot & Ankle Society (AOFAS) Annual Meeting in Seattle, expanding its Foot & Ankle portfolio with two connected technologies.

Prophecy Surgical Planning has processed more than 100,000 ankle cases over 14 years

Stryker's Prophecy platform, used in patient-specific surgical planning, has supported over 100,000 ankle procedures since its introduction 14 years ago, according to internal company data. The tool is now integrated with the Incompass Total Ankle System, giving surgeons 3D visualization and a choice between resect-through and pin-through fixation within a single connected platform.

Anixa Biosciences Adds Penn Oncologist Carmen Guerra to Advisory Board

Image
Anixa Biosciences Adds Penn Oncologist Carmen Guerra to Advisory Board

San Jose, Calif. – September 19, 2026 -- Anixa Biosciences (NASDAQ: ANIX) has appointed Carmen Guerra, M.D., M.S.C.E., F.A.C.P., to its Cancer Business Advisory Board as the company prepares to advance its breast cancer vaccine into a Phase 2 clinical trial and continues its ovarian cancer CAR-T therapy Phase 1 trial.

Harvard Team Wins James Dyson Award for 60-Second Concussion Screener

Image
Harvard Team Wins James Dyson Award for 60-Second Concussion Screener

Boston – September 19, 2026 -- Three Harvard University students have won the U.S. National title at the James Dyson Award 2026 for Rumble Rims, an infrared eye-tracking headset designed to screen young athletes for possible concussions in about 60 seconds. Radhika Saran, Cleo Pontone, and Sophia DeVito take home $6,500 in national prize money to fund further development of the device.

Alzamend Neuro Regains Nasdaq Listing Compliance With $5.8M Equity

Image
Alzamend Neuro Regains Nasdaq Listing Compliance With $5.8M Equity

Atlanta – – September 19, 2026 -- Alzamend Neuro, Inc. (Nasdaq: ALZN) has regained compliance with Nasdaq's minimum stockholders' equity rule, ending a listing threat that began in March 2026.

Nasdaq confirms Alzamend's equity now exceeds required threshold

Nasdaq's Listing Qualifications Staff issued a notification letter dated September 19, 2026, confirming Alzamend satisfies Listing Rule 5550(b)(1), which requires a minimum stockholders' equity of $2.5 million. Alzamend's Quarterly Report on Form 10-Q for the quarter ended September 19, 2026, filed with the SEC on September 19, 2026, showed stockholders' equity of $5,802,680, more than double the required minimum.

Survey: 75% of Voters Urge Congress to Halt 2027 Medicare Lab Cuts

Secaucus, N.J. – September 19, 2026 -- A new national survey commissioned by Quest Diagnostics (NYSE: DGX) finds that 75% of 1,024 registered voters surveyed consider diagnostic lab testing "very important" to their care, with a bipartisan majority pressing Congress to pass the RESULTS Act before scheduled Medicare payment cuts take effect September 19, 2026.

83% of voters relied on a lab test in the past two years to guide a medical decision

The survey found 96% of registered voters view diagnostic lab tests as important to their or their family's care, while 88% expressed concern if Medicare lab payment rates were set too low. Half of respondents said Medicare seniors, rural communities, and people managing cancer or chronic disease would be hurt most if the cuts take effect.

Study: 80% of AI Health Users Return to Trusted Sites

Image
Study: 80% of AI Health Users Return to Trusted Sites

San Diego – September 19, 2026 -- A new AI Patient Journey Study from Luth Research finds that roughly 80 percent of patients who use AI for health information pair it with other sources, forming a group the firm labels "hybrid researchers." The study tracked more than 1,500 consumers digitally and surveyed over 500 patients to map movement between AI tools, search engines, and health information sites.

AI speeds initial queries but trusted sites close the decision loop

Patients turn to AI first for speed and plain-language answers: 47 percent use it to explore a doctor's explanation more deeply, and 44 percent say asking AI is easier than asking their physician. When preparing for an appointment or making a treatment decision, reliance shifts to established health information sites trusted for clinical accuracy, which are used by 6 in 10 AI users as a companion source.

Alps Dx Hires Sales VP, Opens Richmond HQ to Scale Oral Fluid Testing

Image
Alps Dx Hires Sales VP, Opens Richmond HQ to Scale Oral Fluid Testing

Richmond – September 19, 2026 -- Alps Dx has named 26-year diagnostics industry veteran Pam Lacock as vice president of sales and opened a new 2,030-square-foot headquarters and manufacturing hub in Richmond, Virginia, as the company shifts from product development toward broader commercialization of its oral fluid testing platform.

UpRight Science Names Advisory Board Ahead of Falls Prevention Week

Image
UpRight Science Names Advisory Board Ahead of Falls Prevention Week

West Palm Beach, Fla. – – September 19, 2026 -- UpRight Science has assembled a five-member advisory board to accelerate adoption of its FDA-cleared balance measurement software, timed to Falls Prevention Awareness Week running Sept. 21-25.

Falls remain the top injury cause for older Americans, with 14 million reporting incidents annually

More than 14 million U.S. adults aged 65 and older, roughly one in four, report a fall each year, according to figures cited by the company. UpRight Science positions its technology as a way to make balance measurable and trackable as a clinical biomarker rather than a subjective assessment.

Lutris Pharma to Unveil Phase 2 LUT014 Rash Data at EADV

Image
Lutris Pharma to Unveil Phase 2 LUT014 Rash Data at EADV

Tel Aviv, Israel – September 19, 2026 -- Lutris Pharma will present updated phase 2 clinical data for its topical B-Raf inhibitor LUT014 at the 35th European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria, running September 30 through October 3.

Oral presentation scheduled for October 2 at EADV Congress in Vienna

The randomized, double-blind, placebo-controlled trial results will be delivered in an oral presentation titled 'Acneiform Rash from EGFR Inhibitor Therapy: Durable, Mechanism-Directed Reduction with Topical LUT014 (B-Raf Inhibitor) in a Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial.' The session, Free Communication 6: Pruritus/Adverse Drug Reactions, is set for Friday, September 19, 2026, from 11:25 to 11:35 am CET in Hall N. Anisha Patel, MD, professor of Dermatology at The University of Texas MD Anderson Cancer Center in Houston, will present the data under Abstract ID AS-1328.